Clinical trial
Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors
NCT00003713 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00003713 |
|---|---|
| Title | Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors |
| Official title | A Phase I, Pharmacokinetic, and Treatment Duration and Escalation Study of Intravenous Intoplicine Administered as a 5 to 21-Day Continuous Infusion Every 4 Weeks |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | intoplicine |
| Enrollment | 35 |
| Start date | Aug 1, 1997 |
| First posted | May 3, 2004 |
| Last update posted | Aug 29, 2018 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: